Datopotamab global launch status and generic drug price updates

2025Year6month23Day, the United StatesFDA grantedDatroway (dabrotuzumab-duximab-DXd< span>) Accelerated Approval for the treatment of adult patients with locally advanced or metastatic EGFR mutated non-small cell lung cancer (NSCLC) whose disease has progressed after previously receiving EGFR targeted therapy and platinum-based chemotherapy. The approval was based on two pivotal clinical trials (TROPION‑Lung05 vs. TROPION‑Lung01), the overall response rate (ORR) in these patients was 45% and the median duration of response was 6.5 months.

Datrowayobtained FDA approval for use in 20251 HR positive, HER2 negative advanced or metastatic breast cancer patients were subsequently launched in the EU in April, and Japan also approved this indication. . These expedited approvals demonstrate that Datroway, the first ADC targeting TROP‑2, demonstrates broad potential in the treatment of multiple solid tumors.

Currently, there are Datopotamab generic products on the market for scientific research purposes, which are used for research rather than clinical treatment. For example, MedChemExpress provides 1 mg and the price is about 310 US dollars; Selleck Chemicals The price range of similar products is 970 US dollars/1 mg; BiocompareData shows that there are other suppliers with prices of about 420 US$/mg. Although there are huge differences between these products and clinical drugs, the pricing reference range in the field of scientific research can be seen.

Since Datroway is a newly approved innovative ADC drug, there is no public retail price or medical insurance reimbursement information in the US and European markets, and the cost of a single dose is expected to be thousands to tens of thousands of dollars. As the product enters clinical promotion and medical insurance negotiations, pricing reductions and patient assistance programs are expected in the future. In addition, further approval of the drug in the Asian market (for example, Japan has been approved) will provide a precedent for its introduction and pricing in China and Taiwan. Although scientific research imitations are relatively low-priced, they cannot be used on patients, and clinical drug prices still have to wait for post-marketing information to be disclosed.

Overall, Datroway, as a new type of ADC, has shown significant efficacy in a variety of solid tumors such as non-small cell lung cancer and breast cancer, and has been quickly approved by global regulatory agencies. Although clinical prices have not yet been announced, scientific research imitations are priced at milligram levels of US$1,000, indicating high R&D and manufacturing costs. In the future, medical insurance inclusion and pricing mechanisms will determine patient accessibility.

Reference materials:https://www.fda.gov/drugs/